Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

NCT04001803 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: CAB LA+RPV LA

Sponsor

ViiV Healthcare